Design, synthesis, antibacterial evaluation and docking study of novel 2-hydroxy-3-(nitroimidazolyl)-propyl-derived quinolone

Chemical Biology and Drug Design

Volumn 85, Issue 1, 2015, Pages 79-90

  Li, Qing ^a   Xing, Junhao ^a   Cheng, Haibo ^a   Wang, Hui ^a   Wang, Jing ^a   Wang, Shuai ^a   Zhou, Jinpei ^a   Zhang, Huibin ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

antibacterial activity; docking study; nitroimidazole; quinolone

Indexed keywords

1 CYCLOPROPYL 6 FLUORO 7 [1 [2 HYDROXY 3 (2 METHYL 5 NITRO 1H IMIDAZOL 1 YL)PROPYL]HEXAHYDRO 1H PYRROLO[3,4 B]PYRIDIN 6(2H) 8 METHOXY 4 OXO 1,4 DIHYDROQUINOLINE 3 CARBOXYLIC ACID; 1 CYCLOPROPYL 6 FLUORO 7 [1 [2 HYDROXY 3 (2 METHYL 5 NITRO 1H IMIDAZOL 1 YL)PROPYL]HEXAHYDRO 1H PYRROLO[3,4 B]PYRIDIN 6(2H) YL] 8 METHOXY 4 OXO 1,4 DIHYDROQUINOLINE 3 CARBOXYLIC ACID; 1 CYCLOPROPYL 6 FLUORO 7 [3 [2 HYDROXY 3 (2 METHYL 5 NITRO 1H IMIDAZOL 1 YL)PROPYL](METHYL)AMINO]PIPERIDIN 1H YL] 8 METHOXY 4 OXO 1,4 DIHYDROQUINOLINE 3 CARBOXYLIC ACID; 1 CYCLOPROPYL 6 FLUORO 7 [3 [[2 HYDROXY 3 (2 METHYL 5 NITRO 1H IMIDAZOL 1 YL)PROPYL](METHYL)AMINO]PIPERIDIN 1 YL] 8 METHOXY 4 OXO 1,4 DIHYDROQUINOLINE 3 CARBOXYLIC ACID; 1 CYCLOPROPYL 6 FLUORO 7 [4 [2 HYDROXY 3 (2 METHYL 5 NITRO 1H IMIDAZOL 1 YL)PROPYL] 3 METHYLPIPERAZIN 1 YL] 8 METHOXY 4 OXO 1,4 DIHYDROQUINOLINE 3 CARBOXYLIC ACID; 7 [1 [3 (2 CHLORO 4 NITRO 1H IMIDAZOL 1 YL) 2 HYDROXYPROPYL]HEXAHYDRO 1H PYRROLO[3,4 B]PYRIDIN 6(2H) YL] 1 CYCLOPROPYL 6 FLUORO 8 METHOXY 4 OXO 1,4 DIHYDROQUINOLINE 3 CARBOXYLIC ACID; 7 [3 [[3 (2 CHLORO 4 NITRO 1H IMIDAZOL 1 YL) 2 HYDROXYPROPYL](METHYL)AMINO]PIPERIDIN 1 YL] 1 CYCLOPROPYL 6 FLUORO 8 METHOXY 4 OXO 1,4 DIHYDROQUINOLINE 3 CARBOXYLIC ACID; 7 [4 [3 (2 CHLORO 4 NITRO 1H IMIDAZOL 1 YL) 2 HYDROXYPROPYL] 3 METHYLPIPERAZIN 1 YL] 1 CYCLOPROPYL 6 FLUORO 8 METHOXY 4 OXO 1,4 DIHYDROQUINOLINE 3 CARBOXYLIC ACID; 7 [4 [3 (2 CHLORO 4 NITRO 1H IMIDAZOL 1 YL) 2 HYDROXYPROPYL] 3 METHYLPIPERAZIN 1 YL] 1 ETHYL 6,8 DIFLUORO 4 OXO 1,4 DIHYDROQUINOLINE 3 CARBOXYLIC ACID; 7 [4 [3 (2 CHLORO 4 NITRO 1H IMIDAZOL 1 YL) 2 HYDROXYPROPYL]PIPERAZIN 1 YL] 1 CYCLOPROPYL 6 FLUORO 4 OXO 1,4 DIHYDRO 1,8 NAPHTHYRIDINE 3 CARBOXYLIC ACID; 7 [4 [3 (2 CHLORO 4 NITRO 1H IMIDAZOL 1 YL) 2 HYDROXYPROPYL]PIPERAZIN 1 YL] 1 CYCLOPROPYL 6 FLUORO 4 OXO 1,4 DIHYDROQUINOLINE 3 CARBOXYLIC ACID; 7 [4 [3 (2 CHLORO 4 NITRO 1H IMIDAZOL 1 YL) 2 HYDROXYPROPYL]PIPERAZIN 1 YL] 1 ETHYL 6 FLUORO 4 OXO 1,4 DIHYDROQUINOLINE 1,8 NAPHTHYRIDINE 3 CARBOXYLIC ACID; 7 [4 [3 (2 CHLORO 4 NITRO 1H IMIDAZOL 1 YL) 2 HYDROXYPROPYL]PIPERAZIN 1 YL] 1 ETHYL 6 FLUORO 4 OXO 1,4 DIHYDROQUINOLINE 3 CARBOXYLIC ACID; 7 [4 [3 (2 CHLORO 4 NITRO 1H IMIDAZOL 1 YL) 2 HYDROXYPROPYL]PIPERAZIN 1 YL] 6,8 DIFLUORO 1 (2 FLUOROETHYL) 4 OXO 1,4 DIHYDROQUINOLINE 3 CARBOXYLIC ACID; ANTIINFECTIVE AGENT; GATIFLOXACIN; MOXIFLOXACIN; QUINOLONE DERIVATIVE; UNCLASSIFIED DRUG; NITROIMIDAZOLE DERIVATIVE;

ANTIBACTERIAL ACTIVITY; ARTICLE; BINDING AFFINITY; CELL NUCLEUS; DRUG DESIGN; DRUG SYNTHESIS; ESCHERICHIA COLI; HYDROGEN BOND; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR DOCKING; RING OPENING; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; BIOLOGICAL MODEL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST; SYNTHESIS;

METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; POSIBACTERIA; PUFFINUS AURICULARIS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS;

ANTI-BACTERIAL AGENTS; DRUG DESIGN; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; MOLECULAR DOCKING SIMULATION; MOLECULAR STRUCTURE; NITROIMIDAZOLES; QUINOLONES; STAPHYLOCOCCUS AUREUS;

EID: 84918815441     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/cbdd.12395     Document Type: Article

References (30)

1. Gould I.M., (2008) The epidemiology of antibiotic resistance. Int J Antimicrob Agents; 32 (Suppl. 1): S2-S9.
2. Livermore D.M., (2012) Fourteen years in resistance. Int J Antimicrob Agents; 39: 283-294.
3. Theuretzbacher U., (2011) Resistance drives antibacterial drug development. Curr Opin Pharmacol; 11: 433-438.
4. Klevens R.M., Morrison M.A., Nadle J., Petit S., Gershman K., Ray S., Harrison L.H., et al,. (2007) Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA; 298: 1763-1771.
5. Fridkin S.K., Hageman J.C., Morrison M., Sanza L.T., Como-Sabetti K., Jernigan J.A., Harriman K., Harrison L.H., Lynfield R., Farley M.M., (2005) Methicillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med; 352: 1436-1444.
6. Witte W., Cuny C., Klare I., Nubel U., Strommenger B., Werner G., (2008) Emergence and spread of antibiotic-resistant Gram-positive bacterial pathogens. Int J Med Microbiol; 298: 365-377.
7. Mitscher L.A., (2005) Bacterial topoisomerase inhibitors: quinolone and pyridone antibacterial agents. Chem Rev; 105: 559-592.
8. Andriole V.T., (2005) The quinolones: past, present, and future. Clin Infect Dis; 41 (Suppl. 2): S113-S119.
9. Takiff H., Guerrero E., (2011) Current prospects for the fluoroquinolones as first-line tuberculosis therapy. Antimicrob Agents Chemother; 55: 5421-5429.
10. Kumar R., Kumar A., Jain S., Kaushik D., (2011) Synthesis, antibacterial evaluation and QSAR studies of 7-[4-(5-aryl-1,3,4-oxadiazole-2-yl)piperazinyl] quinolone derivatives. Eur J Med Chem; 46: 3543-3550.
11. Abuo-Rahma Gel D., Sarhan H.A., Gad G.F., (2009) Design, synthesis, antibacterial activity and physicochemical parameters of novel N-4-piperazinyl derivatives of norfloxacin. Bioorg Med Chem; 17: 3879-3886.
12. Foroumadi A., Emami S., Mansouri S., Javidnia A., Saeid-Adeli N., Shirazi F.H., Shafiee A., (2007) Synthesis and antibacterial activity of levofloxacin derivatives with certain bulky residues on piperazine ring. Eur J Med Chem; 42: 985-992.
13. Skugor M.M., Stimac V., Palej I., Lugaric D., Paljetak H.C., Filic D., Modric M., Dilovic I., Gembarovski D., Mutak S., Erakovic Haber V., Holmes D.J., Ivezic-Schoenfeld Z., Alihodzic S., (2010) Synthesis and biological activity of 4-O-acyl derivatives of 14- and 15-membered macrolides linked to omega-quinolone-carboxylic unit. Bioorg Med Chem; 18: 6547-6558.
14. Pavlovic D., Fajdetic A., Mutak S., (2010) Novel hybrids of 15-membered 8a- and 9a-azahomoerythromycin A ketolides and quinolones as potent antibacterials. Bioorg Med Chem; 18: 8566-8582.
15. Hubschwerlen C., Specklin J.L., Sigwalt C., Schroeder S., Locher H.H., (2003) Design, synthesis and biological evaluation of oxazolidinone-quinolone hybrids. Bioorg Med Chem; 11: 2313-2319.
16. Wang Y., Damu G.L., Lv J.S., Geng R.X., Yang D.C., Zhou C.H., (2012) Design, synthesis and evaluation of clinafloxacin triazole hybrids as a new type of antibacterial and antifungal agents. Bioorg Med Chem Lett; 22: 5363-5366.
17. Jazayeri S., Moshafi M.H., Firoozpour L., Emami S., Rajabalian S., Haddad M., Pahlavanzadeh F., Esnaashari M., Shafiee A., Foroumadi A., (2009) Synthesis and antibacterial activity of nitroaryl thiadiazole-gatifloxacin hybrids. Eur J Med Chem; 44: 1205-1209.
18. Foroumadi A., Mansouri S., Emami S., Mirzaei J., Sorkhi M., Saeid-Adeli N., Shafiee A., (2006) Synthesis and antibacterial activity of nitroaryl thiadiazole-levofloxacin hybrids. Arch Pharm; 339: 621-624.
19. Mentese M.Y., Bayrak H., Uygun Y., Mermer A., Ulker S., Karaoglu S.A., Demirbas N., (2013) Microwave assisted synthesis of some hybrid molecules derived from norfloxacin and investigation of their biological activities. Eur J Med Chem; 67: 230-242.
20. Abdel-Aziz A.A., Asiri Y.A., Al-Agamy M.H., (2011) Design, synthesis and antibacterial activity of fluoroquinolones containing bulky arenesulfonyl fragment: 2D-QSAR and docking study. Eur J Med Chem; 46: 5487-5497.
21. Moellering R.C. Jr, (2011) Discovering new antimicrobial agents. Int J Antimicrob Agents; 37: 2-9.
22. Minovski N., Perdih A., Solmajer T., (2012) Combinatorially-generated library of 6-fluoroquinolone analogs as potential novel antitubercular agents: a chemometric and molecular modeling assessment. J Mol Model; 18: 1735-1753.
23. Minovski N., Perdih A., Novic M., Solmajer T., (2013) Cluster-based molecular docking study for in silico identification of novel 6-fluoroquinolones as potential inhibitors against Mycobacterium tuberculosis. J Comput Chem; 34: 790-801.
24. Clinical and Laboratory Standard Institute (2006) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, Approved Guideline, CLSI document M7eA7, 2006, ISBN 1-56238-587-9
25. Morris G.M., Goodsell D.S., Halliday R.S., Huey R., Hart W.E., Belew R.K., Olson A.J., (1998) Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J Comput Chem; 19: 1639-1662.
26. Bax B.D., Chan P.F., Eggleston D.S., Fosberry A., Gentry D.R., Gorrec F., Giordano I., et al,. (2010) Type IIA topoisomerase inhibition by a new class of antibacterial agents. Nature; 466: 935-940.
27. Aleksandrova E.V., Kochergin P.M., (2010) Methods of synthesis of halogenonitroimidazoles (review). Pharm Chem J; 44: 381-386.
28. Kim P., Zhang L., Manjunatha U.H., Singh R., Patel S., Jiricek J., Keller T.H., Boshoff H.I., Barry C.E, 3rd, Dowd C.S., (2009) Structure-activity relationships of antitubercular nitroimidazoles. 1. Structural features associated with aerobic and anaerobic activities of 4- and 5-nitroimidazoles. J Med Chem; 52: 1317-1328.
29. Sasaki H., Haraguchi Y., Itotani M., Kuroda H., Hashizume H., Tomishige T., Kawasaki M., Matsumoto M., Komatsu M., Tsubouchi H., (2006) Synthesis and antituberculosis activity of a novel series of optically active 6-nitro-2,3-dihydroimidazo[2,1-b]oxazoles. J Med Chem; 49: 7854-7860.
30. Fukunishi Y., Mikami Y., Nakamura H., (2005) Similarities among receptor pockets and among compounds: analysis and application to in silico ligand screening. J Mol Graph Model; 24: 34-45.